Compare ZYME & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZYME | PEB |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2017 | 2009 |
| Metric | ZYME | PEB |
|---|---|---|
| Price | $26.58 | $11.34 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 8 |
| Target Price | ★ $28.00 | $12.19 |
| AVG Volume (30 Days) | 1.9M | ★ 2.0M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 0.35% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $134,481,000.00 | ★ $1,464,126,000.00 |
| Revenue This Year | $65.21 | $2.25 |
| Revenue Next Year | $20.39 | $2.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 116.21 | 0.99 |
| 52 Week Low | $9.03 | $7.42 |
| 52 Week High | $28.49 | $15.12 |
| Indicator | ZYME | PEB |
|---|---|---|
| Relative Strength Index (RSI) | 73.43 | 57.59 |
| Support Level | $21.89 | $10.46 |
| Resistance Level | $28.49 | $11.58 |
| Average True Range (ATR) | 1.53 | 0.35 |
| MACD | 0.65 | 0.06 |
| Stochastic Oscillator | 84.61 | 74.79 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.